We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

125 hedge funds and large institutions have $1.4B invested in Ventyx Biosciences in 2022 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 53 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,551% more call options, than puts

Call options by funds: $1.62M | Put options by funds: $98K

141% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 22

131% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 16

20% more funds holding

Funds holding: 104125 (+21)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

1% less capital invested

Capital invested by funds: $1.41B → $1.4B (-$12.9M)

4.47% less ownership

Funds ownership: 79.74%75.27% (-4.5%)

Holders
125
Holders Change
+21
Holders Change %
+20.19%
% of All Funds
2.01%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.1%
New
37
Increased
53
Reduced
22
Closed
16
Calls
$1.62M
Puts
$98K
Net Calls
+$1.52M
Net Calls Change
+$1.8M
Name Holding Trade Value Shares
Change
Change in
Stake
CIC
76
Carnegie Investment Counsel
Ohio
$515K +$465K +15,708 New
New York State Common Retirement Fund
77
New York State Common Retirement Fund
New York
$507K -$127K -4,287 -22%
UBS AM
78
UBS AM
Illinois
$502K +$453K +15,300 New
DekaBank Deutsche Girozentrale
79
DekaBank Deutsche Girozentrale
Germany
$494K
CPM
80
Connective Portfolio Management
New York
$492K +$444K +15,000 New
US Bancorp
81
US Bancorp
Minnesota
$466K +$421K +14,199 New
Deutsche Bank
82
Deutsche Bank
Germany
$429K +$92.3K +3,116 +31%
MIM
83
MetLife Investment Management
New Jersey
$427K
Janney Montgomery Scott
84
Janney Montgomery Scott
Pennsylvania
$425K -$235K -7,927 -38%
CS
85
Credit Suisse
Switzerland
$422K +$377K +12,739 +10,031%
Mirae Asset Global Investments
86
Mirae Asset Global Investments
South Korea
$421K +$42.4K +1,433 +13%
AIG
87
American International Group
New York
$387K +$34.2K +1,154 +11%
Principal Financial Group
88
Principal Financial Group
Iowa
$380K +$343K +11,583 New
Barclays
89
Barclays
United Kingdom
$355K +$231K +7,787 +255%
GT
90
Glenmede Trust
Pennsylvania
$341K +$308K +10,390 New
MA
91
MYDA Advisors
New York
$328K +$296K +10,000 New
VOYA Investment Management
92
VOYA Investment Management
Georgia
$307K +$16.7K +563 +6%
Invesco
93
Invesco
Georgia
$284K +$52K +1,755 +25%
SG Americas Securities
94
SG Americas Securities
New York
$262K +$124K +4,192 +111%
ProShare Advisors
95
ProShare Advisors
Maryland
$259K +$234K +7,893 New
Legal & General Group
96
Legal & General Group
United Kingdom
$242K +$139K +4,689 +174%
FM
97
Freemont Management
Switzerland
$233K +$210K +7,107 New
Renaissance Technologies
98
Renaissance Technologies
New York
$223K +$29.6K +1,000 +17%
MC
99
Moors & Cabot
Massachusetts
$216K +$17.8K +600 +10%
AC
100
Avestar Capital
New York
$212K +$192K +6,469 New

VTYX Hedge Fund Activity: Q4 2022 in Review

125 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q4 2022, worth a combined $1.4B — down 0.91% from $1.41B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new VTYX positions and 16 closed out — a net gain of 21 holders — while 53 added to existing stakes and 22 trimmed.

The largest buyer was Capital International Investors, opening a new position worth an estimated $62.6M. The largest seller was Third Point, cutting an estimated $98.1M.

  • 125 institutional investors held Ventyx Biosciences (VTYX) as of Q4 2022, up from 104 in Q3 2022.
  • Funds reported $1.4B of Ventyx Biosciences stock for Q4 2022, down 0.91% quarter-over-quarter.
  • 37 funds opened new Ventyx Biosciences positions in Q4 2022 and 16 closed out, a net change of +21 holders.
  • The largest Ventyx Biosciences buyer in Q4 2022 was Capital International Investors, an estimated $62.6M added.
  • The largest Ventyx Biosciences seller in Q4 2022 was Third Point, an estimated $98.1M sold.

Based on aggregated 13F filings for Q4 2022.